Chinese Anti-Cancer Association guidelines for holistic integrative management of cancer: prostate cancer (2026 edition)
Abstract
Prostate cancer is one of the most common malignancies among men worldwide. In China, the number of newly diagnosed cases continues to increase, while a relatively high proportion of patients still present with advanced disease, resulting in a growing disease burden. With advances in prostate-specific antigen-based early detection, multiparametric magnetic resonance imaging, prostate-specific membrane antigen-targeted molecular imaging, molecular pathology, and genomic testing, as well as the continuing development of surgery, radiotherapy, next-generation hormonal therapy, chemotherapy, molecularly targeted therapy, and radioligand therapy, the management of prostate cancer has progressively shifted toward risk stratification, precision treatment, and whole-course disease management. To further standardize the clinical management of prostate cancer in China, the Male Genitourinary Cancer Committee of the Chinese Anti-Cancer Association convened a multidisciplinary panel comprising experts in urologic surgery, medical oncology, radiation oncology, radiology, pathology, nuclear medicine, traditional Chinese medicine, and rehabilitation medicine to periodically update the previous version of the guideline. The guideline was registered on the Practice Guideline Registration for Transparency platform. The development group searched for and appraised relevant evidence from China and other countries, reviewed authoritative clinical practice guidelines and expert consensuses, and formulated recommendations through multidisciplinary discussions, taking into account the disease characteristics, clinical practice, and availability of healthcare resources in China. The guideline covers epidemiology and risk-adapted early detection, diagnosis and staging, pathological assessment and molecular testing, treatment of localized prostate cancer, management of recurrence after radical therapy, systemic treatment of advanced disease, management of skeletal-related events, integrative Chinese and Western medicine, rehabilitation, and follow-up. Major updates in the 2026 edition include risk-adapted early detection; biopsy decision-making guided by multiparametric magnetic resonance imaging and prostate-specific antigen density; molecular classification and genomic testing; perioperative treatment for high-risk localized disease; risk stratification and salvage treatment after radical therapy; treatment intensification for metastatic hormone-sensitive prostate cancer; precision treatment and therapeutic sequencing for metastatic castration-resistant prostate cancer; prostate-specific membrane antigen-targeted radioligand therapy; and integrative Chinese and Western medicine and whole-course rehabilitation. This guideline is intended to provide healthcare professionals at different levels of medical institutions in China with evidence-based and clinically applicable recommendations that incorporate individual patient characteristics, thereby promoting standardized, precise, and integrative management of prostate cancer.
Related
- 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA): Developed by the task force on the management of cardiovascular disease and chronic kidney disease of the European Society of Cardiology (ESC)
- 2025 American Thyroid Association Management Guidelines for Adult Patients With Differentiated Thyroid Cancer: What's New for Surgeons?
- 2026 Focused Update of the Saudi Heart Association Guidelines on Best Practices in the Management of Chronic Coronary Syndromes.
- Integrative Multi-Omics Reveals TSPAN13 as a Candidate Epithelial–Mesenchymal Transition-Associated Regulator in Prostate Cancer
- Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management
BibTeX
@article{committee2026chinese,
title = {{Chinese Anti-Cancer Association guidelines for holistic integrative management of cancer: prostate cancer (2026 edition)}},
author = {Chinese Anti-Cancer Association Genital Oncology Committee},
journal = {Zhongguo aizheng zazhi},
year = {2026},
month = sep,
url = {http://www.china-oncology.com/zh/article/doi/10.19401/j.cnki.1007-3639.2026.09.010/},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Chinese Anti-Cancer Association guidelines for holistic integrative management of cancer: prostate cancer (2026 edition)
AU - Chinese Anti-Cancer Association Genital Oncology Committee
PY - 2026
DA - 2026/09/01
JO - Zhongguo aizheng zazhi
UR - http://www.china-oncology.com/zh/article/doi/10.19401/j.cnki.1007-3639.2026.09.010/
AB - Prostate cancer is one of the most common malignancies among men worldwide. In China, the number of newly diagnosed cases continues to increase, while a relatively high proportion of patients still present with advanced disease, resulting in a growing disease burden. With advances in prostate-specific antigen-based early detection, multiparametric magnetic resonance imaging, prostate-specific membrane antigen-targeted molecular imaging, molecular pathology, and genomic testing, as well as the continuing development of surgery, radiotherapy, next-generation hormonal therapy, chemotherapy, molecularly targeted therapy, and radioligand therapy, the management of prostate cancer has progressively shifted toward risk stratification, precision treatment, and whole-course disease management. To further standardize the clinical management of prostate cancer in China, the Male Genitourinary Cancer Committee of the Chinese Anti-Cancer Association convened a multidisciplinary panel comprising experts in urologic surgery, medical oncology, radiation oncology, radiology, pathology, nuclear medicine, traditional Chinese medicine, and rehabilitation medicine to periodically update the previous version of the guideline. The guideline was registered on the Practice Guideline Registration for Transparency platform. The development group searched for and appraised relevant evidence from China and other countries, reviewed authoritative clinical practice guidelines and expert consensuses, and formulated recommendations through multidisciplinary discussions, taking into account the disease characteristics, clinical practice, and availability of healthcare resources in China. The guideline covers epidemiology and risk-adapted early detection, diagnosis and staging, pathological assessment and molecular testing, treatment of localized prostate cancer, management of recurrence after radical therapy, systemic treatment of advanced disease, management of skeletal-related events, integrative Chinese and Western medicine, rehabilitation, and follow-up. Major updates in the 2026 edition include risk-adapted early detection; biopsy decision-making guided by multiparametric magnetic resonance imaging and prostate-specific antigen density; molecular classification and genomic testing; perioperative treatment for high-risk localized disease; risk stratification and salvage treatment after radical therapy; treatment intensification for metastatic hormone-sensitive prostate cancer; precision treatment and therapeutic sequencing for metastatic castration-resistant prostate cancer; prostate-specific membrane antigen-targeted radioligand therapy; and integrative Chinese and Western medicine and whole-course rehabilitation. This guideline is intended to provide healthcare professionals at different levels of medical institutions in China with evidence-based and clinically applicable recommendations that incorporate individual patient characteristics, thereby promoting standardized, precise, and integrative management of prostate cancer.
SN - 1007-3639
ER -